ReviewJournal of thrombosis and thrombolysis2021
Serotonin: a platelet hormone modulating cardiovascular disease.
Review in Journal of thrombosis and thrombolysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Meta-analysis on inflammation and autonomic nervous system of coronary heart disease combined with depression.BMJ open · 2024Pooled it
- Efficacy and Safety of Sarpogrelate on Symptom Improvement in Patients with Peripheral Arterial Disease (PAD) and/or Being at Risk of PAD: A Single Arm, Multi-Centered, Open-Label Trial.Current vascular pharmacology · 2025Trial
- Serotonin in Cardiovascular Disease: From Pathophysiological Insights to Clinical Utility.Diagnostics (Basel, Switzerland) · 2026Review
- Selective serotonin re-uptake inhibitors and risks of post-operative hematoma after elbow fracture surgery.JSES international · 2026Article
- Characterization of multi-stage metabolic alterations in hepatitis B virus-related acute-on-chronic liver failure using high-coverage metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Trait impulsivity and risk of cardiovascular disease over 8 years: results from the NutriNet-Santé cohort.European journal of epidemiology · 2026Article
- Article
- Role of central and peripheral serotonin in liver physiology and diseases.Theranostics · 2026Review
- Thromboembolic events with olanzapine: a systematic review integrating meta-analysis and FAERS database.Frontiers in cardiovascular medicine · 2026Review
- The Bidirectional Relationship Between Myocardial Infarction and Depression: Risk Factors, Mechanisms, and Interventions.Biomedicines · 2025Review
- Role of Serotonin, Membrane Transporter, and 5-HT2 Receptors in Pathogenesis of Atherosclerotic Plaque Formation in Immature Heterozygous Low-Density Lipoprotein-Receptor-Deficient Mice.International journal of molecular sciences · 2025Article
- Article
- Investigating psychological difference between two genders in mental health after percutaneous coronary intervention for elderly patients with acute coronary syndrome.Journal of cardiothoracic surgery · 2025Article
- Effects of the 5-Hydroxytryptamine 3 Receptor Antagonist Palonosetron on Hemostasis: An In Vitro Study Using Thromboelastography.Medicina (Kaunas, Lithuania) · 2025Article
- Serotonin receptor 5-HT7 modulates inflammatory-associated functions of macrophages.Cellular and molecular life sciences : CMLS · 2025Article
- Exploring molecular characteristics and interactions of blood stasis syndrome in ischemic heart failure by integrated multi-omics.Frontiers in molecular biosciences · 2025Article
- The tryptophan metabolic pathway of the microbiome and host cells in health and disease.International immunology · 2024Review
- Dietary Polyphenols and Gut Microbiota Cross-Talk: Molecular and Therapeutic Perspectives for Cardiometabolic Disease: A Narrative Review.International journal of molecular sciences · 2024Review
- Review
- Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities.Clinical and translational medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cardiovascular diseases and depression are significant health burdens and increasing evidence suggests a causal relationship between them. The incidence of depression among patients suffering from cardiovascular disease is markedly elevated, and depression itself is an established cardiovascular risk factor. Serotonin 5-hydroxytryptamin (5-HT), a biogenic amine acting as a neurotransmitter and a peripheral hormone, is involved in the pathogenesis of both, cardiovascular disease and depression. Novel cardiovascular functions of 5-HT have recently been described and will be summarized in this review. 5-HT has a broad spectrum of functions in the cardiovascular system, yet the clinical or experimental data are partly conflicting. There is further research needed to characterize the clinical effects of 5-HT in particular tissues to enable targeted pharmacological therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.